Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)

China flag China · Delayed Price · Currency is CNY
29.36
-0.24 (-0.81%)
At close: Jan 21, 2026
18.24%
Market Cap10.58B
Revenue (ttm)225.16M
Net Income (ttm)-583.52M
Shares Out366.68M
EPS (ttm)-1.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,844,607
Average Volume3,835,742
Open29.47
Previous Close29.60
Day's Range29.20 - 29.92
52-Week Range22.79 - 37.88
Beta0.81
RSI48.75
Earnings DateApr 30, 2026

About SHA:688443

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a mo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 743
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688443
Full Company Profile

Financial Performance

In 2024, SHA:688443's revenue was 30.09 million, an increase of 2384.11% compared to the previous year's 1.21 million. Losses were -797.27 million, -0.50% less than in 2023.

Financial Statements